keyword
MENU ▼
Read by QxMD icon Read
search

primary progressive multiple sclerosis

keyword
https://www.readbyqxmd.com/read/28641926/targeting-the-gm-csf-receptor-for-the-treatment-of-cns-autoimmunity
#1
Igal Ifergan, Todd S Davidson, Hania Kebir, Dan Xu, Daphne Palacios-Macapagal, Jennifer Cann, Jane M Rodgers, Zoe N Hunter, Camille L Pittet, Sara Beddow, Clare A Jones, Alexandre Prat, Matthew A Sleeman, Stephen D Miller
In multiple sclerosis (MS), there is a growing interest in inhibiting the pro-inflammatory effects of granulocyte-macrophage colony-stimulating factor (GM-CSF). We sought to evaluate the therapeutic potential and underlying mechanisms of GM-CSF receptor alpha (Rα) blockade in animal models of MS. We show that GM-CSF signaling inhibition at peak of chronic experimental autoimmune encephalomyelitis (EAE) results in amelioration of disease progression. Similarly, GM-CSF Rα blockade in relapsing-remitting (RR)-EAE model prevented disease relapses and inhibited T cell responses specific for both the inducing and spread myelin peptides, while reducing activation of mDCs and inflammatory monocytes...
June 19, 2017: Journal of Autoimmunity
https://www.readbyqxmd.com/read/28641503/embolization-of-a-large-progressive-symptomatic-desmoid-tumor-in-the-rectus-muscle-of-a-female-patient-with-multiple-sclerosis-a-case-report
#2
I Diebels, M Blockhuys, P Willemsen, Y Pirenne
INTRODUCTION: Desmoid tumors are benign tumors, yet can lead to significant morbidity due to aggressive local expansions. Treatment starts with a wait-and-see policy, however, more aggressive treatments like broad margin resection surgery might be necessary in case of tumor progression. PATIENTS AND METHODS: We report the case of a 26-year-old female with a symptomatic desmoid tumor in the left rectus muscle. The initial wait-and-see policy led to an increase in tumor size and progression of symptoms...
June 22, 2017: Acta Chirurgica Belgica
https://www.readbyqxmd.com/read/28639535/corrigendum
#3
(no author information available yet)
Cawley N, Tur C, Prados F, et al. Spinal cord atrophy as a primary outcome measure in phase II trials of progressive multiple sclerosis. Mult Scler. Epub ahead of print 18 May 2017. DOI: 10.1177/1352458517709954. On page 9 of this article, the Declaration of Conflicting Interests and Funding statements were incorrect. The correct declarations are shown below. Declaration of Conflicting Interests The author(s) declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: A...
June 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28638709/-cure-for-multiple-sclerosis-ms-evolving-views-of-therapy-goals-in-patients-on-different-stages-of-the-disease-a-pilot-study-in-a-cohort-of-polish-ms-patients
#4
Weronika Chacińska, Marta Brzostowska, Monika Nojszewska, Aleksandra Podlecka-Piętowska, Wiesław W Jędrzejczak, Emilian Snarski
INTRODUCTION: New aggressive treatments promise improvement of results in the treatment of multiple sclerosis (MS), however, with high risk of serious complications. In this study, we analyzed patients' acceptance for risks connected with the MS treatment. METHODS: The study was designed as a prospective nonanonymous online questionnaire. Responders were asked about the definition of the "cure" for MS and crucial goals in the treatment. RESULTS: One hundred and eighty patients filled in the questionnaire (129 women and 51 men), and the mean age was 33 years (SD = 10...
June 2017: Brain and Behavior
https://www.readbyqxmd.com/read/28633629/prevalence-of-and-risk-factors-for-severe-cognitive-and-sleep-symptoms-in-me-cfs-and-ms
#5
Vageesh Jain, Amit Arunkumar, Caroline Kingdon, Eliana Lacerda, Luis Nacul
BACKGROUND: There are considerable phenotypic and neuroimmune overlaps between myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and multiple sclerosis (MS). While the precise aetiologies of both MS and ME/CFS are unclear, evidence suggests that deterioration in cognitive function is widely prevalent in patients with either condition. Little is known about differing risk factors or exposures, which may lead to severe cognitive or sleep symptoms. This study aims to gauge the extent of cognitive and sleep symptoms in ME/CFS and MS patients participating in the UK ME/CFS Biobank and identify the characteristics of those experiencing severe symptoms...
June 20, 2017: BMC Neurology
https://www.readbyqxmd.com/read/28624334/seasonality-and-autoimmune-diseases-the-contribution-of-the-four-seasons-to-the-mosaic-of-autoimmunity
#6
REVIEW
Abdulla Watad, Shir Azrielant, Nicola Luigi Bragazzi, Kassem Sharif, Paula David, Itay Katz, Gali Aljadeff, Mariana Quaresma, Galya Tanay, Mohammad Adawi, Howard Amital, Yehuda Shoenfeld
Autoimmune diseases (ADs) are a heterogeneous groups of diseases that occur as a results of loss of tolerance to self antigens. While the etiopathogeneis remain obscure, different environmental factors were suggested to have a role in the development of autoimmunity, including infections, low vitamin D levels, UV radiation, and melatonin. Interestingly, such factors possess seasonal variation patterns that could influence disease development, severity and progression. Vitamin D levels which reach a nadir during late winter and early spring is correlated with increased disease activity, clinical severity as well as relapse rates in several disease entities including multiple sclerosis (MS), non-cutaneous flares of systemic lupus erythematosus (SLE), psoriasis, and rheumatoid arthritis (RA)...
June 14, 2017: Journal of Autoimmunity
https://www.readbyqxmd.com/read/28620346/primary-progressive-multiple-sclerosis-putting-together-the-puzzle
#7
REVIEW
Ahmed Abdelhak, Martin S Weber, Hayrettin Tumani
The focus of multiple sclerosis research has recently turned to the relatively rare and clearly more challenging condition of primary progressive multiple sclerosis (PPMS). Many risk factors such as genetic susceptibility, age, and Epstein-Barr virus (EBV) infection may interdepend on various levels, causing a complex pathophysiological cascade. Variable pathological mechanisms drive disease progression, including inflammation-associated axonal loss, continuous activation of central nervous system resident cells, such as astrocytes and microglia as well as mitochondrial dysfunction and iron accumulation...
2017: Frontiers in Neurology
https://www.readbyqxmd.com/read/28617991/interferon-%C3%AE-regulates-the-production-of-il-10-by-toll-like-receptor-activated-microglia
#8
Diogo Lobo-Silva, Guilhermina M Carriche, A Gil Castro, Susana Roque, Margarida Saraiva
Pattern recognition receptors, such as toll-like receptors (TLRs), perceive tissue alterations and initiate local innate immune responses. Microglia, the resident macrophages of the brain, encode TLRs which primary role is to protect the tissue integrity. However, deregulated activation of TLRs in microglia may lead to chronic neurodegeneration. This double role of microglial responses is often reported in immune-driven neurologic diseases, as in multiple sclerosis (MS). Consequently, strategies to manipulate microglia inflammatory responses may help to ameliorate disease progression...
June 15, 2017: Glia
https://www.readbyqxmd.com/read/28617364/-a-current-view-on-the-mri-diagnosis-of-multiple-sclerosis-an-update-of-2016-revised-mri-criteria
#9
V V Bryukhov, I A Krotenkova, S N Morozova, M V Krotenkova
Magnetic resonance imaging (MRI) is the primary method for confirming the clinical diagnosis of multiple sclerosis (MS). The article presents the current data on using MRI of the brain and spinal cord for diagnosis in suspected MS. Special attention is paid to the MRI criteria of McDonald and MAGNIMS for relapsing-remitting MS (RRMS) and primary-progressive MS (PPMS) in the latest revisions of 2010 and 2016. The information provided can help radiologists and neurologists to optimize the use of MRI in clinical practice for diagnosis of MS...
2017: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/28617357/-polymorphic-variants-of-the-immune-response-genes-as-risk-factors-for-primary-progressive-multiple-sclerosis
#10
E V Popova, I S Kiselev, A N Boyko, S A Sivertseva, N A Malkova, D S Korobko, N N Spirin, D S Kasatkin, A V Karaeva, E L Turova, N N Spirina, L I Volkova, N M Baulina, V V Bashinskaya, O G Kulakova, O O Favorova
AIM: To analyze the involvement of immune response genes in the pathogenesis of primary progressive multiple sclerosis (PPMS). MATERIAL AND METHODS: This multicenter study included 111 patients with PPMS from the Russian ethnic group. The association of PPMS with genes of immune system was analyzed by the study of polymorphic variants of genes of cytokines and genes of antigen-presenting cells. RESULTS AND CONCLUSION: The genotypes of IL-4 (rs2243250)*C/C and CLEC16A (rs6498169)*G/G were associated with PPMS in Russians...
2017: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/28610655/the-diagnosis-and-treatment-of-sj%C3%A3-gren-s-syndrome
#11
Ana-Luisa Stefanski, Christian Tomiak, Uwe Pleyer, Thomas Dietrich, Gerd Rüdiger Burmester, Thomas Dörner
BACKGROUND: Sjögren's syndrome is one of the more common inflammatory rheumatological diseases, with a prevalence of at least 0.4% in Germany. METHODS: This review is based on pertinent articles retrieved by a selective search in PubMed. Special attention is drawn to updated classification criteria and current treatment recommendations. RESULTS: Sjögren's syndrome has a wide variety of presentations, ranging from the local involvement of exocrine glands with keratoconjunctivitis sicca and xerostomia (the leading signs of the disease) to the systemic, extraglandular involvement of multiple organs...
May 26, 2017: Deutsches Ärzteblatt International
https://www.readbyqxmd.com/read/28607759/a-composite-measure-to-explore-visual-disability-in-primary-progressive-multiple-sclerosis
#12
Valentina Poretto, Maria Petracca, Catarina Saiote, Enricomaria Mormina, Jonathan Howard, Aaron Miller, Fred D Lublin, Matilde Inglese
BACKGROUND: Optical coherence tomography (OCT) and magnetic resonance imaging (MRI) can provide complementary information on visual system damage in multiple sclerosis (MS). OBJECTIVES: The objective of this paper is to determine whether a composite OCT/MRI score, reflecting cumulative damage along the entire visual pathway, can predict visual deficits in primary progressive multiple sclerosis (PPMS). METHODS: Twenty-five PPMS patients and 20 age-matched controls underwent neuro-ophthalmologic evaluation, spectral-domain OCT, and 3T brain MRI...
April 2017: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/28578514/the-beneficial-effects-of-hmg-coa-reductase-inhibitors-in-the-processes-of-neurodegeneration
#13
REVIEW
Seyed Soheil Saeedi Saravi, Seyed Sobhan Saeedi Saravi, Alireza Arefidoust, Ahmad Reza Dehpour
Statins, cholesterol lowering drugs, have been demonstrated to exert beneficial effects in other conditions such as primary and progressing neurodegenerative diseases beyond their original role. Observation that statins ameliorate the neurodegenerative diseases such as Parkinson's disease (PD), Alzheimer's disease (AD), multiple sclerosis (MS) and cerebral ischemic stroke, the neuroprotective effects of these drugs are thought to be linked to their anti-inflammatory, anti-oxidative, and anti-excitotoxic properties...
June 3, 2017: Metabolic Brain Disease
https://www.readbyqxmd.com/read/28578105/aberrant-expression-of-%C3%AE-catenin-in-cd4-t-cells-isolated-from-primary-progressive-multiple-sclerosis-patients
#14
Sabrina Giacoppo, Oxana Bereshchenko, Stefano Bruscoli, Carlo Riccardi, Placido Bramanti, Emanuela Mazzon
Primary progressive multiple sclerosis (PP-MS) is a less common progressive form of MS in approximately 10% of patients that manifest increasingly neurological disability from disease onset. To date, there are no approved treatments for the progressive stage. Therefore, identifying new therapeutic targets could open a new opportunity for PP-MS management. Several lines of evidence suggest the critical role of the Wnt/β-catenin pathway in immune-mediated diseases, like MS. This study was aimed to investigate whether aberrant expression of β-catenin is involved in PP-MS progression...
May 31, 2017: Neuroscience Letters
https://www.readbyqxmd.com/read/28569645/in-vivo-evidence-of-oxidative-stress-in-brains-of-patients-with-progressive-multiple-sclerosis
#15
In-Young Choi, Phil Lee, Peter Adany, Abbey J Hughes, Scott Belliston, Douglas R Denney, Sharon G Lynch
BACKGROUND: The oxidative stress hypothesis links neurodegeneration in the later, progressive stages of multiple sclerosis (MS) to the loss of a major brain antioxidant, glutathione (GSH). OBJECTIVE: We measured GSH concentrations among major MS subtypes and examined the relationships with other indices of disease status including physical disability and magnetic resonance imaging (MRI) measures. METHODS: GSH mapping was performed on the fronto-parietal region of patients with relapsing-remitting multiple sclerosis (RRMS, n = 21), primary progressive multiple sclerosis (PPMS, n = 20), secondary progressive multiple sclerosis (SPMS, n = 20), and controls ( n = 28) using GSH chemical shift imaging...
June 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28566952/prevalence-of-multiple-sclerosis-in-the-middle-black-sea-region-of-turkey-and-demographic-characteristics-of-patients
#16
Neslihan Akdemir, Murat Terzi, Nilden Arslan, Musa Onar
INTRODUCTION: Multiple sclerosis (MS), a demyelinating disease of the central nervous system, is increasing in prevalence worldwide. Other than small-scale studies, there is a scarcity of data on the prevalence of MS in Turkey. The present study aimed to elucidate the prevalence of MS in the Middle Black Sea Region and the demographic characteristics of patients. METHODS: Patients living in the Middle Black Sea Region and who were diagnosed with MS were included...
March 2017: Noro Psikiyatri Arsivi
https://www.readbyqxmd.com/read/28561175/-multiple-sclerosis-fatigue-its-neural-correlates-and-its-modulation-with-tdcs
#17
Samar S Ayache, Moussa A Chalah, Tania Kümpfel, Frank Padberg, Jean-Pascal Lefaucheur, Ulrich Palm
Multiple sclerosis (MS) is a chronic progressive and inflammatory disease of the central nervous system and causes high rates of non-traumatic disability in young adults. Fatigue is frequently reported by a major part of patients during the disease course and dramatically increases the burden of illness. Despite the high prevalence of fatigue and its enormous impact on quality of life, its pathophysiological mechanisms are still unclear. Its etiology is multifactorial and complex, and is usually classified into 'primary' fatigue resulting from the pathological brain changes versus 'secondary' fatigue following disease symptoms, sleep disturbances, mood disorders, and side effects of medication...
May 2017: Fortschritte der Neurologie-Psychiatrie
https://www.readbyqxmd.com/read/28529497/efficacy-and-safety-of-fingolimod-in-daily-practice-experience-of-an-academic-ms-french-center
#18
Thomas Roux, Elisabeth Maillart, Jean-Sébastien Vidal, Sophie Tezenas du Montcel, Catherine Lubetzki, Caroline Papeix
INTRODUCTION: Fingolimod (Fg), a sphingosine 1-phosphate receptor modulator, decreases the annual relapse rate (ARR) in relapsing-remitting multiple sclerosis (RRMS). The aim of this study was to assess the efficacy and safety of Fg in daily practice in patients with RRMS, previously treated with natalizumab (Nz) or not, and systematically followed during at least 1 year. METHODS: Data were collected from the patient files. Primary endpoint was the comparison between the ARR the year before Fg onset and after 1 and 2 years of Fg treatment...
2017: Frontiers in Neurology
https://www.readbyqxmd.com/read/28524746/a-contemporary-profile-of-primary-progressive-multiple-sclerosis-participants-from-the-narcoms-registry
#19
Amber Salter, Nina P Thomas, Tuula Tyry, Gary R Cutter, Ruth Ann Marrie
BACKGROUND: Primary progressive multiple sclerosis (PPMS) represents 10%-15% of all multiple sclerosis (MS) diagnoses. Information regarding socio-demographic and clinical characteristics of persons with PPMS is limited. OBJECTIVE: To characterize persons with PPMS in the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry. METHODS: We compared demographic and health-related characteristics of NARCOMS Registry participants reporting PPMS in the spring 2015 update survey with those reporting relapsing-remitting multiple sclerosis (RRMS) and secondary progressive multiple sclerosis (SPMS), with characteristics of published PPMS cohorts...
May 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28523586/ocrelizumab-first-global-approval
#20
James E Frampton
Ocrelizumab (Ocrevus™) is a humanised anti-CD20 monoclonal antibody that has been developed by Genentech, Inc. (a subsidiary of Roche) for the treatment of multiple sclerosis (MS). The drug is designed to deplete B cells, which play an important role in the pathogenesis of MS. In March 2017, ocrelizumab was approved in the USA for the treatment of patients with relapsing or primary progressive forms of MS; currently, it is awaiting approval in the EU for the same indications. This article summarizes the milestones in the development of ocrelizumab leading to its first global approval for the treatment of MS...
June 2017: Drugs
keyword
keyword
93616
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"